EA200601223A1 - Производные сульфонамида для лечения заболеваний - Google Patents

Производные сульфонамида для лечения заболеваний

Info

Publication number
EA200601223A1
EA200601223A1 EA200601223A EA200601223A EA200601223A1 EA 200601223 A1 EA200601223 A1 EA 200601223A1 EA 200601223 A EA200601223 A EA 200601223A EA 200601223 A EA200601223 A EA 200601223A EA 200601223 A1 EA200601223 A1 EA 200601223A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
diseases
sulfonamide
treatment
disorders
Prior art date
Application number
EA200601223A
Other languages
English (en)
Other versions
EA011167B1 (ru
Inventor
Алан Дэниел Браун
Марк Эдвард Баннэйдж
Пол Алан Глоссоп
Ким Джеймс
Шарлотт Элис Луиз Лейн
Расселл Эндрю Льютвайт
Ян Брайан Моузес
Дэвид Энтони Прайс
Николас Мюррей Томсон
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601223(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA200601223A1 publication Critical patent/EA200601223A1/ru
Publication of EA011167B1 publication Critical patent/EA011167B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

Данное изобретение относится к соединениям формулы (1) и к способам получения таких производных, содержащим их композициям и применению таких производных. Соединения согласно настоящему изобретению пригодны в случае многочисленных заболеваний, нарушений и состояний, в частности воспалительных, аллергических и респираторных заболеваний, нарушений и состояний.
EA200601223A 2004-01-22 2005-01-12 Производные сульфонамида для лечения заболеваний EA011167B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
PCT/IB2005/000086 WO2005080313A2 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (2)

Publication Number Publication Date
EA200601223A1 true EA200601223A1 (ru) 2006-12-29
EA011167B1 EA011167B1 (ru) 2009-02-27

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601223A EA011167B1 (ru) 2004-01-22 2005-01-12 Производные сульфонамида для лечения заболеваний

Country Status (30)

Country Link
US (4) US7244766B2 (ru)
EP (1) EP1708991B1 (ru)
JP (1) JP4020954B2 (ru)
AP (1) AP2359A (ru)
AR (1) AR047509A1 (ru)
AT (1) ATE375977T1 (ru)
AU (1) AU2005214153B2 (ru)
BR (1) BRPI0507085A (ru)
CA (1) CA2553789C (ru)
DE (1) DE602005002930T2 (ru)
DK (1) DK1708991T3 (ru)
DO (1) DOP2005000006A (ru)
EA (1) EA011167B1 (ru)
ES (1) ES2293530T3 (ru)
GE (1) GEP20094781B (ru)
MY (1) MY143390A (ru)
NL (1) NL1028087C2 (ru)
NO (1) NO20062983L (ru)
NZ (1) NZ548318A (ru)
OA (1) OA13362A (ru)
PA (1) PA8622001A1 (ru)
PE (1) PE20051136A1 (ru)
PL (1) PL1708991T3 (ru)
PT (1) PT1708991E (ru)
RS (1) RS50561B (ru)
SI (1) SI1708991T1 (ru)
TW (1) TWI341831B (ru)
UA (1) UA84048C2 (ru)
UY (1) UY28721A1 (ru)
WO (1) WO2005080313A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214153B2 (en) * 2004-01-22 2008-09-18 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
US20080193988A1 (en) * 2005-07-18 2008-08-14 Iain Robert Gladwell Process for the Preparation of Sulfonamide Derivatives
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
RU2442771C2 (ru) 2005-08-08 2012-02-20 Арджента Дискавери Лтд Производные бицикло[2,2,1]гепт-7-иламина и их применения
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SI2379507T1 (sl) 2008-12-30 2014-02-28 Pulmagen Therapeutics (Inflammation) Limited Spojine sulfonamida za zdravljenje respiratornih motenj
KR20120018813A (ko) 2009-05-29 2012-03-05 화이자 리미티드 글루코코티코이드 수용체 작용제
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013021309A1 (en) 2011-08-11 2013-02-14 Pfizer Limited Intermediate and process for the preparation of a sulfonamide derivative
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US229058A (en) * 1880-06-22 spencer
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CN1268942A (zh) * 1997-06-27 2000-10-04 藤泽药品工业株式会社 磺酰胺化合物及其药物用途
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
DE10244972B4 (de) * 2002-03-26 2013-02-28 The Japan Steel Works, Ltd. Wärmefester Stahl und Verfahren zur Herstellung desselben
AU2003239880A1 (en) * 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
AU2005214153B2 (en) * 2004-01-22 2008-09-18 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases

Also Published As

Publication number Publication date
ES2293530T3 (es) 2008-03-16
TW200530165A (en) 2005-09-16
ATE375977T1 (de) 2007-11-15
US20100273758A1 (en) 2010-10-28
MY143390A (en) 2011-05-13
DK1708991T3 (da) 2008-01-14
WO2005080313A2 (en) 2005-09-01
AP2006003669A0 (en) 2006-06-30
US7528170B2 (en) 2009-05-05
JP2007518789A (ja) 2007-07-12
NL1028087C2 (nl) 2006-05-09
DOP2005000006A (es) 2005-07-31
US8013019B2 (en) 2011-09-06
US20090197912A1 (en) 2009-08-06
DE602005002930D1 (de) 2007-11-29
AU2005214153B2 (en) 2008-09-18
DE602005002930T2 (de) 2008-07-24
NO20062983L (no) 2006-07-24
PA8622001A1 (es) 2005-08-30
BRPI0507085A (pt) 2007-06-19
AR047509A1 (es) 2006-01-25
EA011167B1 (ru) 2009-02-27
WO2005080313A9 (en) 2006-08-31
US20050182091A1 (en) 2005-08-18
GEP20094781B (en) 2009-09-25
UA84048C2 (ru) 2008-09-10
JP4020954B2 (ja) 2007-12-12
PT1708991E (pt) 2007-12-14
PL1708991T3 (pl) 2008-02-29
WO2005080313A3 (en) 2005-12-01
US7767715B2 (en) 2010-08-03
UY28721A1 (es) 2005-08-31
CA2553789A1 (en) 2005-09-01
EP1708991B1 (en) 2007-10-17
PE20051136A1 (es) 2006-02-18
AU2005214153A1 (en) 2005-09-01
US20080267970A1 (en) 2008-10-30
TWI341831B (en) 2011-05-11
RS50561B (sr) 2010-05-07
EP1708991A2 (en) 2006-10-11
NL1028087A1 (nl) 2005-07-25
SI1708991T1 (sl) 2008-02-29
OA13362A (en) 2007-04-13
CA2553789C (en) 2011-07-19
AP2359A (en) 2012-01-30
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17

Similar Documents

Publication Publication Date Title
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
EA200601462A1 (ru) Соединения для лечения заболеваний
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
EA200870282A1 (ru) Производные амина
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
EA200900337A1 (ru) Сульфонамидные производные в качестве адренергических агонистов и мускариновых антагонистов
EA200601868A1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов
TW200607506A (en) Tetrahydronaphthyridine derivatives
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
EA200601510A1 (ru) Производные фенилэтаноламина в качестве бета-2-агонистов
EA200501615A1 (ru) (2-гидрокси-2-(4-гидрокси-3-гидроксиметилфенил)этиламино)пропилфенильные производные в качестве бета-2-агонистов
EA200501399A1 (ru) Производные бензопирана, которые могут использоваться при лечении воспалительных заболеваний
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
ATE440836T1 (de) Verbindungen
EA200601544A1 (ru) Производные формамида, пригодные в качестве адренорецептора
UA86615C2 (en) Formamide derivatives useful as adrenoceptor
NO20064805L (no) Sammensetninger for behandling av sykdommer
ECSP066700A (es) Derivados de sulfonamida para el tratamiento de enfermedades
UA84748C2 (ru) 3- или 4-монозамещенные фенол и тиофенолпроизводные, полезные как н3 лиганды
CR8513A (es) Derivados de sulfonamida para el tratamiento de enfermedades
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU